Sleep medications and psilocybin.
28 records in this group. 2 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Overview
Reviewed 2026-10-25Sleep medications work in different ways. Z-drugs (zolpidem, eszopiclone, zaleplon) and benzodiazepines act on GABA-A, the brain's main inhibitory system; orexin blockers (suvorexant, lemborexant, daridorexant) block wake-promoting signals; sedating antihistamines (diphenhydramine, doxylamine, hydroxyzine) are also anticholinergic; and melatonin, ramelteon and tasimelteon act on melatonin receptors. Each adds sedation if still active during a session. Benzodiazepines combined with opioids can cause profound sedation, slowed breathing, coma and death (temazepam prescribing information).
Zolpidem's label carries a boxed warning for complex sleep behaviors such as sleepwalking and sleep-driving, including some resulting in serious injury or death, and describes hallucinations and withdrawal symptoms after abrupt stopping (Ambien prescribing information). Benzodiazepine labels carry a boxed warning that abrupt stopping or rapid dose reduction can cause withdrawal reactions, including seizures (temazepam prescribing information). Suvorexant's label describes sleep paralysis and hallucinations at sleep onset (Belsomra prescribing information).
Trazodone and mirtazapine block 5-HT2A, the serotonin receptor psilocybin acts on, and one systematic review anticipates that they reduce psychedelic effects (Halman 2024). With LSD, 28 of 32 people who had taken an SSRI or trazodone for more than 3 weeks, at antidepressant doses, reported a reduced or absent response in a retrospective questionnaire (Bonson 1996). No study has tested low bedtime doses. Zolpidem appears in one multi-drug case report, alongside phenelzine, nortriptyline, lithium and other drugs, in which psilocybin mushrooms produced no noticeable subjective effects; the report does not separate the drugs' effects (Barnett 2024).
Quetiapine, often used at low doses for sleep, is an antipsychotic; Colorado's rule names antipsychotic medications without distinguishing dose or reason for use, and quetiapine is covered on the antipsychotics page. Low-dose doxepin is a tricyclic; see the tricyclics page.
Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.
- Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18.
- Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996;14:425–436.
- Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
- Temazepam capsules prescribing information (DailyMed)
- Ambien (zolpidem) prescribing information (DailyMed)
- Belsomra (suvorexant) prescribing information (DailyMed)
Also searched as sleeping pill · sleep aid · sleep medication · sleeping pills
01 What the evidence covers
Best evidence available per medication| 2 | Case reports Case reports or online surveys |
| 26 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZOccasional headaches and minor aches and pains with accompanying sleeplessness
It causes drowsiness and may cause confusion with psilocybin. The acetaminophen part has no known psilocybin interaction.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- CBD / CBNEvidence: No psilocybin data
Anxiety; Chronic pain
CBD may slow how the body clears psilocybin, more so at higher doses. Also, it can cause sleepiness; full-spectrum products contain trace THC.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Insomnia (trouble falling or staying asleep)
Not studied with psilocybin; no linking mechanism is described. Also, it causes next-day sleepiness and can cause sleep paralysis or hallucinations at sleep-wake transitions.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Hay fever and upper respiratory allergy symptoms; Common cold symptoms (runny nose, sneezing)
Its drowsiness and confusion may add to psilocybin's effects, though it has no meaningful serotonin effect. Also, it raises heart rate.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression; Anxiety
In theory it blunts psilocybin, but related tricyclics strengthened LSD responses. Also, it sedates and affects heart rhythm; 3–6 mg acts mainly as an antihistamine.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Trouble falling asleep (occasional sleeplessness); Nausea and vomiting of pregnancy (with pyridoxine, Rx)
It is sedating and may cause confusion or delirium during psilocybin's altered state.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- EstazolamEvidence: No psilocybin data
Insomnia (short-term)
It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Insomnia
It may add sedation if still active during a psilocybin session (not studied with psilocybin). Also, its label warns of complex sleep behaviors like sleep-driving.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- FlurazepamEvidence: No psilocybin data
Insomnia
It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Anxiety and tension; Itching from allergic skin conditions (hives, eczema, contact dermatitis)
Its sleepiness and confusion may add to psilocybin's effects. Also, it can cause heart-rhythm (QT) effects, more so with other drugs that do this.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Occasional sleeplessness associated with minor aches and pains
Its diphenhydramine causes drowsiness and may cause confusion under psilocybin. Also, regular ibuprofen use can raise blood pressure, as psilocybin briefly does.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Insomnia (trouble falling or staying asleep)
Its sedation may add to psilocybin's effects; it has no serotonin effect. Also, its label describes hallucinations around sleep and more suicidal thoughts than placebo.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- MelatoninEvidence: No psilocybin data
Jet lag; Delayed sleep timing (delayed sleep-wake phase disorder)
Not studied with psilocybin; no linking mechanism is described. Also, it causes mild sedation.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression
It blocks the receptor psilocybin works through, so it may weaken psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Occasional sleeplessness associated with minor aches and pains
It causes drowsiness and may cause confusion with psilocybin; regular naproxen use can raise blood pressure, as psilocybin briefly does.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Insomnia (trouble falling or staying asleep, or early waking)
It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Schizophrenia; Bipolar I disorder (manic episodes)
It blocks the receptor psilocybin works through, so it is expected to weaken psilocybin's effects. Stopping it suddenly after regular use can cause withdrawal.
CO: named in rule · OR: not mentioned in rule · NM: rules not final
Insomnia (trouble falling asleep)
Not studied with psilocybin; no linking mechanism is described.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Insomnia (trouble falling or staying asleep)
Not studied with psilocybin; no linking mechanism is described; it is sedating. Also, its label notes sleep-onset hallucinations and complex sleep behaviors.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Non-24-hour sleep-wake disorder (adults); Nighttime sleep disturbances in Smith-Magenis syndrome (capsules age 16+; oral suspension ages 3-15)
Not studied with psilocybin; no linking mechanism is described.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Insomnia (short-term)
It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (major depressive disorder)
In one case, nightly trazodone blocked psilocybin's psychedelic effects; it blocks the receptor psilocybin works through. Also, it can affect heart rhythm and blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Insomnia (short-term, generally 7 to 10 days, adults)
It adds sedation; untested with psilocybin (midazolam, the one studied, partly impaired memory of the session). Stopping it suddenly can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- ValerianEvidence: No psilocybin data
Insomnia (sleep); Anxiety
Valerian may add sedation to psilocybin (not studied). Stopping it suddenly after regular use may cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Insomnia (short-term, trouble falling asleep)
It causes sedation and may make psilocybin feel weaker if still in the body. Also, its label reports hallucinations and worsening depression.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Insomnia with trouble falling asleep (short-term); Insomnia with trouble staying asleep (extended-release)
In one case, psilocybin mushrooms with zolpidem, phenelzine and other drugs had no noticeable effect. Its sedation may overlap a session.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
It causes sedation and may make psilocybin feel weaker if still in the body. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 26 | Sedating or CNS depressant |
| 16 | Withdrawal or rebound if stopped abruptly |
| 15 | Psychiatric reactions |
| 8 | Anticholinergic |
| 5 | QT-prolonging |
| 4 | Lowers blood pressure or causes orthostasis |
| 3 | Blocks 5-HT2A (may blunt effects) |
| 3 | Liver injury |
| 3 | Lowers seizure threshold or carries seizure risk |
| 3 | Serotonergic |
| 2 | Dehydration or electrolyte risk |
| 2 | Raises blood pressure or heart rate |
| 1 | UGT inhibition (theoretical effect on psilocin levels) |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governs1 of 28 named by a provision.
Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “antipsychotic medications” and does not limit this by indication or dose. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).
Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 19 of the 28 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRelated classes
- Antihistamines and allergy pills6 shared
- Benzodiazepines6 shared
- Antidepressants3 shared
- Pain relievers3 shared
Records reviewed 2026-09-30 to 2026-10-14. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z